Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: KEGG:D02027 (Tranilast)
 205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tranilast is an orally effective anti-allergic agent evaluated for clinical activity in prevention of symptoms of allergic rhinitis. It was investigated in a randomized, pre-seasonal, and in-seasonal treatment of tranilast to test the clinical efficacy and pathophysiological changes on the onset of nasal symptoms in season. Thirty-eight patients with a history of Sugi pollinosis and positive allergic tests were treated with tranilast 300 mg daily 6 to 7 weeks before the onset of the pollen season and continuously during the season or no medication including tranilast until the onset of clinical symptoms in season. The number of sneezing and the grade of stuffiness at the onset of pollen season were inhibited significantly in pre-seasonal treatment. The number of mast cells and eosinophils in season increased compared with off-season and the threshold of nasal hypersensitivity in season decreased compared with off-season in inseasonal treatment, but not in pre-seasonal treatment. This study indicates that tranilast may have the prophylactic effect for Sugi pollinosis.
 ...
PMID:Clinical and pathophysiological evaluation of tranilast in patients with pollinosis: the effects of pre-seasonal treatment. 751 12

N(3',4'-dimethoxycinnamoyl) anthranilic acid (Tranilast) inhibits antibody-mediated hypersensitivity reactions, and is an effective drug for patients with bronchial asthma or allergic rhinitis. Interferon-gamma (IFN-gamma) production of ovalbumin (OA)-stimulated peripheral blood mononuclear cells (PBMCs) from hen's egg-sensitive patients with atopic dermatitis (AD) was significantly higher than those of healthy controls. Tranilast inhibited this IFN-gamma production. Moreover, interleukin-2 (IL-2) production of OA-stimulated PBMCs from hen's egg-sensitive patients with AD was also inhibited by Tranilast. Our results suggest that Tranilast can be used to the patients with food sensitive AD.
 ...
PMID:Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis. 754 77

Gyokuheifu-san (GHS; Jade Windscreen Powder in English, Yupingfeng-san in Chinese) is an herbal formula in traditional Chinese medicine that consolidates the superficial resistance to protect from invasion by external pathogenic influences. We evaluated the preventive and curative effects of GHS on allergic rhinitis induced by Japanese cedar pollens in guinea pigs, since the pollen can be considered one of external pathogens indicated by GHS. Guinea pigs were sensitized by intranasal instillation of cedar pollen extract with alum twice a day for 7 d, and the animals were then forced to inhale the pollens for challenge once a week for 5 weeks. We administered GHS once a day for 2 weeks in the period of sensitization to evaluate its preventive effect, or for 2 weeks from the 2nd to the 4th week of pollen inhalation, once pollinosis had begun, to evaluate its curative effect on allergic rhinitis. GHS significantly suppressed the frequency of sneezing induced by pollens and tended to reduce nose-scratching behavior after ceasing its administration in both designs of medicinal treatment. Tranilast, which is an anti-allergic drug we used as a positive control, could not suppress these rhinitic symptoms. GHS appears to have non-symptomatic and non-allopathic effects on allergic rhinitis. Our results suggest that traditional medicines have their own characteristics different from modern medicines, and the original pharmacological experiments are important to evaluate traditional medicines scientifically.
 ...
PMID:Preventive and curative effects of Gyokuheifu-san, a formula of traditional Chinese medicine, on allergic rhinitis induced with Japanese cedar pollens in guinea pig. 1505 65

Kissei, in collaboration with SmithKline Beecham, is developing tranilast (Rizaben) as a prophylactic agent for restenosis, following percutaneous transluminal coronary angioplasty (PTCA). As of May 1997, tranilast was awaiting approval in Japan as an oral formulation given for three months following PTCA [246273], [248281]. The agent has been launched for use in allergic rhinitis, asthma and atopic dermatitis. Analysts had expected the early approval of Rizaben for PTCA-associated restenosis. However, due to delays by the Ministry of Health and Welfare, it is unlikely that Rizaben will be approved until the end of 1998. Sales of Rizaben for the treatment of its launched indications did not reach company expectations. The companies are also developing tranilast, in a nasal spray formulation, as a potential treatment for allergic rhinitis. The drug is in phase II trials for this indication [262810]. EP-00588518 from Kissei discloses the use of tranilast for the treatment of restenosis. Kissei has also filed patents disclosing the use of tranilast for arteriosclerosis (JP-09227371) and diabetic retinopathy (WO-09729744).
 ...
PMID:Tranilast Kissei Pharmaceutical. 1846 19